SKIN SkinHealth Systems Inc.
SkinHealth Systems Inc., a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America. The company's flagship product is HydraFacial, which enhances the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. It also offers Syndeo devices, which are delivery systems that are designed to connect providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling and nanoneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive peptide solutions and take home sprays for treating scalp health. In addition, it operates the MyBeautyHealth mobile application for consumers to earn loyalty points and unlock savings, log skin concerns and receive personalized treatment plans, and find and connect with Hydrafacial providers, as well as offers boosters. The company was formerly known as The Beauty Health Company and changed its name to SkinHealth Systems Inc. in April 2026. The company was founded in 1997 and is headquartered in Long Beach, California.…
Industry Peers
Household & Personal ProductsKey Statistics
About SkinHealth Systems (NASDAQ: SKIN)
›
SkinHealth Systems (NASDAQ: SKIN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Household & Personal Products industry, part of the Consumer Defensive sector, and reports about 613 employees.
The shares were at 12.15 USD on 19 November 2026, down 58.7% over 52 weeks. Its 52-week range is 9.680 USD to 34.80 USD: the price is 65.1% below the high and 25.5% above the low.
Its market capitalisation is 79.16M USD.
SkinHealth Systems reports return on equity of -15.6%, an operating margin of 2.4% and revenue down 2.1% year over year.
Its debt exceeds its cash by 152.85M USD, a debt-to-equity ratio of 6.20. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Hold; their mean price target of 14.50 USD is 19.3% above the current price. The next earnings report is expected on 11 March 2027.